Anything is better than nothing': exploring attitudes towards novel therapies in leukodystrophy clinical trials.

Autor: Wilson E; The University of Melbourne, Melbourne, VIC, Australia. ella.wilson@monashivfgroup.com., Leventer R; Murdoch Children's Research Institute, Melbourne, VIC, Australia.; Australian Genomics, Melbourne, VIC, Australia.; Royal Children's Hospital, Melbourne, VIC, Australia.; The University of Melbourne, Melbourne, VIC, Australia., Cunningham C; Murdoch Children's Research Institute, Melbourne, VIC, Australia.; Royal Children's Hospital, Melbourne, VIC, Australia.; Victorian Clinical Genetics Services, Melbourne, VIC, Australia.; The University of Melbourne, Melbourne, VIC, Australia., de Silva MG; Murdoch Children's Research Institute, Melbourne, VIC, Australia.; Victorian Clinical Genetics Services, Melbourne, VIC, Australia.; The University of Melbourne, Melbourne, VIC, Australia., Hodgson J; The University of Melbourne, Melbourne, VIC, Australia., Uebergang E; Murdoch Children's Research Institute, Melbourne, VIC, Australia.; Australian Genomics, Melbourne, VIC, Australia.
Jazyk: angličtina
Zdroj: Orphanet journal of rare diseases [Orphanet J Rare Dis] 2024 Sep 05; Vol. 19 (1), pp. 322. Date of Electronic Publication: 2024 Sep 05.
DOI: 10.1186/s13023-024-03320-9
Abstrakt: Background/aim: Leukodystrophies comprise a group of genetic white matter disorders that lead to progressive motor and cognitive impairment. Recent development of novel therapies has led to an increase in clinical trials for leukodystrophies. To enable recruitment of individuals with a leukodystrophy into clinical trials, clinical trial acceptability should be ascertained. We sought therefore, to identify the motivations for and barriers to clinical trial participation in addition to clinical trial features that may be of concern to individuals with a leukodystrophy and/or their carers.
Methods: Adults with a leukodystrophy and parents/carers of individuals with a leukodystrophy were recruited through the Australian Leukodystrophy Registry and through online advertisements. Qualitative semi-structured interviews were used to explore participants views on what clinical trials involve, the perceived risks and benefits of clinical trials, their desire to participate in clinical trials and their personal experience with leukodystrophy. Thematic analysis of data was performed with co-coding of interview transcripts.
Results: 5 interviews were held with parents of children with leukodystrophy, 4 with parents of adults with leukodystrophy and 3 with adults diagnosed with leukodystrophy. Motivations for clinical trial enrolment include access to potentially lifesaving novel treatments and improved prognostic outcomes. Participants were concerned about adverse clinical trial outcomes, including side effects and exacerbation of illness. Despite this, majority of participants were willing to try anything in clinical trials, demonstrating a high tolerance for first in human trials and trials utilising invasive treatment options.
Conclusions: Interviewees communicated a strong desire to participate in interventional clinical trials involving novel therapies. To support enrolment into future leukodystrophy clinical trials we suggest the provision of transparent information regarding clinical trial treatments, consideration of alternative trial control measures, and inclusion of treating clinicians in the trial recruitment process. Clinicians play an integral role in initiating transparent conversations regarding trial risks and adverse outcomes.
(© 2024. Crown.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje